This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laakso, M. Articles by Lempiainen-Kuosa, P. Search for Related Content PubMed PubMed Citation Articles by Laakso, M. Articles by Lempiainen-Kuosa, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Hazardous Substances DB LACTIC ACID LOSARTAN POTASSIUM METOPROLOL POTASSIUM

(Hypertension. 1996;28:392-396.)
© 1996 American Heart Association, Inc.

Articles

Effects of Losartan on Insulin Sensitivity in Hypertensive Subjects

Markku Laakso; Leena Karjalainen; Paivi Lempiainen-Kuosa

the Department of Medicine, Kuopio (Finland) University Hospital.

Correspondence to Markku Laakso, MD, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail markku.laakso@uku.fid:\tekstit\losmet95.art.

Losartan, the first specific and orally available angiotensin II receptor antagonist, is a potent antihypertensive drug with a low incidence of side effects in humans. However, the effects of losartan on insulin sensitivity and glucose metabolism have not been investigated in detail. Therefore, we carried out a randomized, double-blind study to compare the effects of losartan (50 mg QD) and metoprolol (95 mg QD) on insulin sensitivity, insulin secretion, glucose tolerance, and lipids and lipoproteins in 20 hyperinsulinemic subjects with essential hypertension. The fall in blood pressure was greater with losartan than with metoprolol. Insulin sensitivity evaluated by the euglycemic clamp technique did not change in either group after 12 weeks of treatment. Similarly, glucose oxidation (losartan: 17.0±0.9 versus 16.9±1.0 µmol/kg per minute [before versus after, P=NS]; metoprolol: 17.9±1.3 versus 16.8±1.6 [P=NS]) and nonoxidation (losartan: 22.3±4.0 versus 23.5±3.4 µmol/kg per minute [P=NS]; metoprolol: 23.3±3.2 versus 25.6±4.7 [P=NS]) remained unchanged during the last 30 minutes of the 3-hour euglycemic clamp. Losartan and metoprolol did not have any significant adverse effects on insulin secretion, glucose tolerance, or lipids and lipoproteins. In conclusion, losartan is metabolically neutral, without any significant adverse effect on glucose and lipid metabolism.

Key Words: losartan • metoprolol • insulin • glucose

This article has been cited by other articles:

				D. Yavuz, M. Koc, A. Toprak, I. Akp{iota}nar, A. Velioglu, O. Deyneli, G. Haklar, and S. Akalln Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 197 - 203. [Abstract] [PDF]

				M. P Mulcahy, K. Ahmed, S. Luzio, D. R Owens, and J. H Lazarus Effect of losartan on insulin sensitivity and serum lipids in hypertensive type 2 diabetic patients The British Journal of Diabetes & Vascular Disease, January 1, 2002; 2(1): 67 - 68. [Abstract] [PDF]

				E. J. Henriksen, S. Jacob, T. R. Kinnick, M. K. Teachey, and M. Krekler Selective Angiotensin II Receptor Antagonism Reduces Insulin Resistance in Obese Zucker Rats Hypertension, October 1, 2001; 38(4): 884 - 890. [Abstract] [Full Text] [PDF]

				N. J. Brown, M. Agirbasli, and D. E. Vaughan Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans Hypertension, August 1, 1999; 34(2): 285 - 290. [Abstract] [Full Text] [PDF]